References: US Food and Drug Administration. FDA requires Guillain-Barré syndrome (GBS) warning in the prescribing information for RSV vaccines Abrysvo and Arexvy.

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased risk for Guillain-Barré Syndrome (GBS) within 42 days of vaccination ...

The FDA issued a safety communication that warns about possible Guillain-Barré syndrome (GBS) with respiratory syncytial virus (RSV) vaccines manufactured by Pfizer (Abrysvo) and GSK (Arexvy ...

The FDA is adding a warning about Guillain-Barré syndrome to the respiratory syncytial virus vaccines manufactured by GSK and Pfizer based on data that suggest there may be a link between the ...

This new Shingrix vaccine presentation eliminates the need for reconstitution, simplifying the administration process for ...

Last summer, a group of scientists in Quebec analyzed the risk of Guillain-Barré syndrome in millions of people given the vaccine in Canada between 2009 and 2010 and reported 83 confirmed cases ...

Cite this: MHRA Advises on Rare Guillain-Barré Syndrome Risk After RSV Vaccination - Medscape - July 08, 2025. Comments Commenting is limited to medical professionals.